title: A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.
abstract: OBJECTIVE
  To prospectively evaluate tumor control, survival, and toxic effects in patients with International Federation of Gynecology and Obstetrics (1988) stage I-IIIA papillary serous carcinoma of the endometrium treated with concurrent chemoradiation and adjuvant chemotherapy.
  
  
  METHODS
  Thirty-two patients were enrolled from October 2001 through July 2009. Patients underwent full surgical disease staging and postoperative concurrent weekly paclitaxel (50 mg/m2) and pelvic RT to 45 Gy plus a vaginal cuff boost followed by 4 cycles of adjuvant paclitaxel (135 mg/m2).
  
  
  RESULTS
  Thirty patients (94%) were evaluable (3 with stage IA disease, 11 IB, 3 IC, 1 IIB, and 12 IIIA). Eighteen patients (60%) received all 5 planned courses of concurrent chemotherapy, 10 (33%) received 4 courses, and 2 (7%) received 3 courses. All 30 patients received RT; 27 (90%) received the full dose, 2 received 43.2 Gy, and 1 received 39.6 Gy owing to toxic effects. Twenty-three patients (77%) completed all 4 cycles of adjuvant paclitaxel, 3 (10%) completed 3 cycles, 2 (7%) completed 2 cycles, and 2 received no adjuvant therapy. Overall survival (OS), progression-free survival (PFS), and local control rates for all patients were 93%, 87%, and 87%, respectively, at 2 years and 85%, 83%, and 87%, respectively, at 5years. Six patients developed (20%) grade 3/4 toxicities from the treatment. Four patients (13%) had grade 3 or more severe bowel complications and two patients developed symptomatic pelvic fractures.
  
  
  CONCLUSIONS
  Treatment with concurrent paclitaxel and pelvic RT followed by 4 courses of systemic paclitaxel produced favorable results in patients with surgically staged I-III UPSC.
authors: Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ajhingra@mdanderson.org
authors: Anuja
authors: A
authors: Jhingran
authors: Lois M
authors: LM
authors: Ramondetta
authors: Diane C
authors: DC
authors: Bodurka
authors: Brian M
authors: BM
authors: Slomovitz
authors: Jubilee
authors: J
authors: Brown
authors: Lawrence B
authors: LB
authors: Levy
authors: Michael E
authors: ME
authors: Garcia
authors: Patricia J
authors: PJ
authors: Eifel
authors: Karen H
authors: KH
authors: Lu
authors: Thomas W
authors: TW
authors: Burke
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001918:Brachytherapy / Q000009:adverse effects; D059186:Chemoradiotherapy, Adjuvant / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D018284:Cystadenocarcinoma, Serous / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D007262:Infusions, Intravenous; D008875:Middle Aged; D009367:Neoplasm Staging; D010052:Ovariectomy; D017239:Paclitaxel / Q000627:therapeutic use*; D011446:Prospective Studies; D058994:Salpingectomy; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel
references: Radiother Oncol. 2003 Nov;69(2):201-7
references: 14643959
references: Gynecol Oncol. 2004 Dec;95(3):469-73
references: 15581948
references: Int J Radiat Oncol Biol Phys. 1992;22(3):613-7
references: 1346533
references: Nat Med. 1996 Jan;2(1):72-9
references: 8564846
references: J Natl Cancer Inst. 1994 Mar 16;86(6):441-6
references: 7907149
references: J Clin Oncol. 1997 Mar;15(3):901-7
references: 9060526
references: Semin Oncol. 1996 Dec;23(6 Suppl 16):128-35
references: 9007140
references: Gynecol Oncol. 1996 Mar;60(3):438-42
references: 8774654
references: Gynecol Oncol. 1993 Dec;51(3):383-9
references: 8112650
references: Gynecol Oncol. 2005 Sep;98(3):353-9
references: 16005947
references: Gynecol Oncol. 2008 Feb;108(2):298-305
references: 18096209
references: Gynecol Oncol. 2003 Sep;90(3):537-46
references: 13678721
references: Gynecol Oncol. 2011 Dec;123(3):542-7
references: 21963091
references: Gynecol Oncol. 2003 Dec;91(3):470-5
references: 14675664
references: Radiother Oncol. 2009 Nov;93(2):207-12
references: 19766338
references: Lancet. 2010 Mar 6;375(9717):816-23
references: 20206777
references: Gynecol Oncol. 2006 Aug;102(2):195-9
references: 16647748
references: Gynecol Oncol. 1997 Nov;67(2):131-6
references: 9367695
references: Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1330-7
references: 11955746
references: Gynecol Oncol. 2003 Dec;91(3):463-9
references: 14675663
references: Cancer. 2009 May 15;115(10):2119-27
references: 19306417
references: Gynecol Oncol. 2004 Dec;95(3):593-6
references: 15581969
references: Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):77-84
references: 9422561
references: Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1439-45
references: 15275730
references: Gynecol Oncol. 2004 Aug;94(2):383-6
references: 15297176
references: Gynecol Oncol. 1992 Sep;46(3):317-21
references: 1526508
references: Cancer J. 2008 May-Jun;14(3):200-6
references: 18536561
references: Gynecol Oncol. 2001 Jul;82(1):156-61
references: 11426978
references: Br J Obstet Gynaecol. 1989 Aug;96(8):889-92
references: 2775686
references: Gynecol Oncol. 1999 Aug;74(2):272-7
references: 10419744
references: Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1354-60
references: 12873680